Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome

Phase 2 Completed 28 enrolled Western Sydney Local Health District

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The main purpose of this study is to assess the efficacy of metformin in abrogating androgen deprivation therapy (ADT) induced insulin resistance as measured by homeostasis model assessment (HOMAIR) in men with non-metastatic prostate cancer.

Timeline

Start: 2010-02
Primary completion: 2013-06
Completion: 2013-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	1500 mg	—

Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome

Summary

Timeline

Drugs

Indications